Frovatriptan

Frovatriptan
Clinical data
Trade names	Frova
Other names	6-methylamino-6,7,8,9-tetrahydro-5H-carbazole-3-carboxamide; (6R)-6-methylamino-6,7,8,9-tetrahydro-5H-carbazole-3-carboxamide
AHFS/Drugs.com	Monograph
MedlinePlus	a604013
Pregnancy; category	AU: B3; ;
Routes of; administration	Oral
ATC code	N02CC07 (WHO) ;
Legal status
Legal status	In general: ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	20–30%
Metabolism	Hepatic
Elimination half-life	26 hours
Excretion	Renal
Identifiers
	show IUPAC name
CAS Number	158747-02-5 ; succinate: 158930-17-7 ;
PubChem CID	77992;
IUPHAR/BPS	7191;
DrugBank	DB00998 ;
ChemSpider	70378 ;
UNII	H82Q2D5WA7; succinate: D28J6W18HY ;
KEGG	D07997 ;
ChEMBL	ChEMBL1279 ;
CompTox Dashboard (EPA)	DTXSID0023080 ;
Chemical and physical data
Formula	C14H17N3O
Molar mass	243.310 g·mol−1
3D model (JSmol)	Interactive image;
	show SMILES
	show InChI
	(what is this?)

Frovatriptan, sold under the brand name Frova, is a triptan drug developed by Vernalis for the treatment of migraine headaches^[1] and for short term prevention of menstrual migraine.^[2] The product is licensed to Endo Pharmaceuticals in North America and Menarini in Europe.^[3]

Medical uses[]

Frovatriptan is used in the treatment of migraine.

Available forms[]

It is available as 2.5 mg tablets.

Contraindications[]

Frovatriptan should not be given to patients with:

Ischemic heart disease
Cerebrovascular syndrome
Peripheral vascular disease
Uncontrolled hypertension
Hemiplegic or basilar migraine

Side effects[]

Rare, but serious cardiac events have been reported in patients with risk factors predictive of CAD. These include: coronary artery vasospasm, transient myocardial ischemia, myocardial infarction, ventricular tachycardia and ventricular fibrillation.

Pharmacology[]

Pharmacodynamics[]

Frovatriptan is a serotonin receptor agonist, with high affinity for the 5-HT_1B/1D receptors. It has no significant effects on the GABA_A mediated channel activity and benzodiazepine binding sites. Frovatriptan inhibits excessive dilation of arteries that supply blood to the head.

Pharmacokinetics[]

Frovatriptan has mean terminal elimination half-life of approximately 26 hours, which is substantially longer than other triptans.^{[citation needed]}

Society and culture[]

US licensing[]

Frovatriptan is available only by prescription in the United States and Canada, where a secondary New Drug Approval (sNDA) was filed in July 2006.^[4]

References[]

^ Allais G, Benedetto C (2016). "Spotlight on frovatriptan: a review of its efficacy in the treatment of migraine". Drug Design, Development and Therapy. 10: 3225–3236. doi:10.2147/DDDT.S105932. PMC 5055118. PMID 27757013.
^ MacGregor EA (2014). "A review of frovatriptan for the treatment of menstrual migraine". International Journal of Women's Health. 6: 523–35. doi:10.2147/IJWH.S63444. PMC 4039425. PMID 24904224.
^ "Frova". Vernalis. Archived from the original on 2007-09-27. Retrieved 2007-11-28.
^ "Patient Information Sheet -- Frovatriptan succinate (marketed as Frova)". Food and Drug Administration. July 2006. Archived from the original on 2007-09-29. Retrieved 2007-11-28.

External links[]

Frova (manufacturer's website)
Frovatriptan Succinate (patient information)
FDA labeling

[pmid27757013-1] Allais G, Benedetto C (2016). "Spotlight on frovatriptan: a review of its efficacy in the treatment of migraine". Drug Design, Development and Therapy. 10: 3225–3236. doi:10.2147/DDDT.S105932. PMC 5055118. PMID 27757013.

[pmid24904224-2] MacGregor EA (2014). "A review of frovatriptan for the treatment of menstrual migraine". International Journal of Women's Health. 6: 523–35. doi:10.2147/IJWH.S63444. PMC 4039425. PMID 24904224.

[3] "Frova". Vernalis. Archived from the original on 2007-09-27. Retrieved 2007-11-28.

[4] "Patient Information Sheet -- Frovatriptan succinate (marketed as Frova)". Food and Drug Administration. July 2006. Archived from the original on 2007-09-29. Retrieved 2007-11-28.

[1]

[2]

[3]

[4]